Expression of angiopoietin-like 4 fibrinogen-like domain (cANGPTL4) increases risk of brain metastases in women with breast cancer.
blood-brain barrier
brain metastases
breast cancer
cANGPTL4
vascular permeability
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
05 May 2020
05 May 2020
Historique:
received:
27
11
2019
accepted:
19
03
2020
entrez:
15
5
2020
pubmed:
15
5
2020
medline:
15
5
2020
Statut:
epublish
Résumé
Brain metastases challenge daily clinical practice, and the mechanisms by which cancer cells cross the blood-brain barrier remain largely undeciphered. Angiopoietin-like 4 (ANGPTL4) proteolytic fragments have controversial biological effects on endothelium permeability. Here, we studied the link between ANGPTL4 and the risk of brain metastasis in cancer patients. From June 2015 to June 2016, serum samples from 113 cancer patients were prospectively collected, and ANGPTL4 concentrations were assessed. Using a murine model of brain metastases, we investigated the roles of nANGPTL4 and cANGPTL4, the two cleaved fragments of ANGPTL4, in the occurrence of brain metastases. An ANGPTL4 serum concentration over 0.1 ng/mL was associated with decreased overall-survival. Multivariate analyses found that only breast cancer brain metastases were significantly associated with elevated ANGPTL4 serum concentrations. 4T1 murine breast cancer cells were transfected with either In this study, we showed that a higher expression of Angiopoietin-like 4 Fibrinogen-Like Domain (cANGPTL4) was associated with an increased risk of brain metastases in women with breast cancer.
Sections du résumé
BACKGROUND
BACKGROUND
Brain metastases challenge daily clinical practice, and the mechanisms by which cancer cells cross the blood-brain barrier remain largely undeciphered. Angiopoietin-like 4 (ANGPTL4) proteolytic fragments have controversial biological effects on endothelium permeability. Here, we studied the link between ANGPTL4 and the risk of brain metastasis in cancer patients.
MATERIALS AND METHODS
METHODS
From June 2015 to June 2016, serum samples from 113 cancer patients were prospectively collected, and ANGPTL4 concentrations were assessed. Using a murine model of brain metastases, we investigated the roles of nANGPTL4 and cANGPTL4, the two cleaved fragments of ANGPTL4, in the occurrence of brain metastases.
RESULTS
RESULTS
An ANGPTL4 serum concentration over 0.1 ng/mL was associated with decreased overall-survival. Multivariate analyses found that only breast cancer brain metastases were significantly associated with elevated ANGPTL4 serum concentrations. 4T1 murine breast cancer cells were transfected with either
CONCLUSIONS
CONCLUSIONS
In this study, we showed that a higher expression of Angiopoietin-like 4 Fibrinogen-Like Domain (cANGPTL4) was associated with an increased risk of brain metastases in women with breast cancer.
Identifiants
pubmed: 32405335
doi: 10.18632/oncotarget.27553
pii: 27553
pmc: PMC7210011
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1590-1602Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST Authors have no conflicts of interest to delcare.
Références
J Clin Pathol. 2010 Dec;63(12):1054-8
pubmed: 20861003
Breast Cancer Res Treat. 2008 May;109(2):231-9
pubmed: 17638068
Oncotarget. 2017 Jul 5;8(44):75778-75796
pubmed: 29100268
Oncogene. 2014 Apr 24;33(17):2273-8
pubmed: 23686315
Exp Eye Res. 1977;25 Suppl:1-25
pubmed: 73470
J Clin Oncol. 2009 Nov 1;27(31):5278-86
pubmed: 19770385
FASEB J. 2009 Mar;23(3):940-9
pubmed: 19019854
Int J Cardiol. 2015;187:511-6
pubmed: 25863293
J Clin Oncol. 2014 Jul 1;32(19):2100-8
pubmed: 24799487
J Clin Invest. 2019 Nov 1;129(11):4593-4608
pubmed: 31545295
Clin Cancer Res. 2015 Feb 15;21(4):916-24
pubmed: 25501128
FEBS Lett. 2005 Oct 24;579(25):5621-5
pubmed: 16213495
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Angiogenesis. 2014 Jan;17(1):261-74
pubmed: 24114199
Nature. 2005 Jul 28;436(7050):518-24
pubmed: 16049480
Int J Cancer. 2015 Jul 15;137(2):332-44
pubmed: 25529931
PLoS One. 2013 Apr 23;8(4):e62576
pubmed: 23626836
Circulation. 2012 Jan 3;125(1):140-9
pubmed: 22086875
Eur Heart J. 2013 Dec;34(47):3657-68
pubmed: 23674618
Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1134-9
pubmed: 19932944
Int J Mol Sci. 2019 Dec 18;21(1):
pubmed: 31861465
Oncol Rep. 2010 Sep;24(3):599-606
pubmed: 20664963
Pathol Oncol Res. 2019 Jul 1;:
pubmed: 31264122
Oncogene. 2012 Apr 5;31(14):1757-70
pubmed: 21860410
Clin Cancer Res. 2012 Apr 15;18(8):2290-300
pubmed: 22374331
Hepatology. 2011 Sep 2;54(3):910-9
pubmed: 21674552
Mol Cancer Res. 2012 Jun;10(6):677-88
pubmed: 22661548
Breast Cancer Res Treat. 2013 Oct;141(3):507-14
pubmed: 24104881
ISRN Surg. 2011;2011:207103
pubmed: 22084749
NPJ Precis Oncol. 2019 Oct 3;3:24
pubmed: 31602400
Eur J Appl Physiol. 2020 Jan;120(1):117-125
pubmed: 31707478
Blood. 2011 Oct 6;118(14):3990-4002
pubmed: 21841165
Breast Cancer Res Treat. 2013 Jun;139(3):677-89
pubmed: 23760857
Mol Cancer Res. 2020 Jan;18(1):79-90
pubmed: 31641008
Mol Cancer. 2014 Aug 22;13:196
pubmed: 25148701
J Mol Med (Berl). 2012 Jul;90(7):803-15
pubmed: 22231744
Cancer Res. 2003 Oct 15;63(20):6651-7
pubmed: 14583458
Cell Biosci. 2011 Feb 25;1(1):8
pubmed: 21711688
Nature. 2009 Jun 18;459(7249):1005-9
pubmed: 19421193
Anticancer Res. 2012 Nov;32(11):4655-62
pubmed: 23155227
J Cell Biol. 1967 Jul;34(1):207-17
pubmed: 6033532
Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18721-6
pubmed: 17130448
mBio. 2019 Jun 4;10(3):
pubmed: 31164474
Gynecol Oncol. 2012 Oct;127(1):210-6
pubmed: 22579791
Exp Ther Med. 2013 Jan;5(1):119-127
pubmed: 23251252
J Biol Chem. 2011 May 6;286(18):15747-56
pubmed: 21398697
Asian Pac J Cancer Prev. 2015;16(18):8579-87
pubmed: 26745120
Cell. 2008 Apr 4;133(1):66-77
pubmed: 18394990